Shares in Zogenix (ZGNX) rallied 7% in Thursday’s after-hours trading after the company shared new data for Fintepla (fenfluramine) oral solution in Dravet syndrome …
Zogenix (ZGNX) is one of the pharma’s biggest losers today. The reason?
The biotech “run-up” trade has always attracted a wide-array of traders looking to take advantage of potentially high alpha price moves before the …
This morning, Zogenix, Inc. (NASDAQ:ZGNX) investors feel like they won the lottery.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, announced receipt of Fast Track designation from …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced new data …
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced that it is implementing …
Biopharmaceutical company Zogenix (NASDAQ: ZGNX) announced on Tuesday that it will be selling its painkiller drug, Zohydro, to Pernix Therapeutics Holdings Inc (NASDAQ: PTX) …
In a research report issued on March 11, Brean Capital analyst Difei Yang reiterated a Buy rating on Zogenix, Inc. (NASDAQ:ZGNX) with a price …
